Innoviva, Inc. (INVA)

Innoviva's Q3 2025 EPS exceeded expectations by 157.14%, with total revenue increasing by 20% compared to Q3 2024. The successful U.S. launch of ZEVTERA strengthened the company's product portfolio. A new $125 million share repurchase program was announced. The FDA accepted the zoliflodacin NDA and granted Priority Review, with positive Phase 3 data published in The Lancet. Innoviva acquired a drug delivery platform from Lyndra Therapeutics and invested in Beacon Biosignals, Inc. Armata Pharmaceuticals announced positive Phase 2 data. Dimensional Fund Advisors LP held 5.8% of Innoviva's shares. Analyst commentary highlighted Innoviva's valuation.

The search results do not explicitly state any significant demand seasonality for Innoviva, Inc.'s products and services. Demand may be relatively steady throughout the year.

Innoviva, Inc. is a diversified holding company in the Healthcare sector, focusing on pharmaceuticals. It manages royalties from respiratory assets and develops/commercializes pharmaceutical products, primarily in critical care and infectious diseases. Major products include RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which generate royalty revenue. GIAPREZA sales increased by 33% from 2023 to 2024. XERAVA has maintained significant growth above 20% since its acquisition. XACDURO received favorable guidelines placement in 2024. ZEVTERA was launched in the U.S. in mid-2025. Zoliflodacin is a late-stage product candidate with a PDUFA target action date of December 15, 2025.

Innoviva, Inc. develops and commercializes pharmaceutical products in the United States and internationally. The company's U.S. net product sales for its Innoviva Specialty Therapeutics (IST) segment have shown robust growth. Historically, a significant portion of its sales has been attributed to Great Britain.

Innoviva's brand reputation is characterized by its mission to deliver innovative medicines to patients with unmet needs, particularly in critical care and infectious diseases. The company emphasizes leveraging its expertise across these areas and respiratory medicine to address critical gaps in healthcare. The successful launches of new products like ZEVTERA and progress in its pipeline, such as zoliflodacin, contribute positively to its reputation as an innovator in areas of high unmet medical need.

Innoviva, Inc. has a highly concentrated ownership structure, with institutional investors holding 99.12% of the ownership as of November 2025. GlaxoSmithKline PLC (GSK) holds a corporate/strategic stake of 42.81%. Insiders held 40.39% of the ownership as of November 2025.